

# MALABAR INDIA FUND LIMITED


4th Floor, 19, Bank Street, Cybercity, Ebene 72201, Mauritius  
Tel: + (230) 404 8800 Fax: + (230) 404 8899 Email: [malabarfund@apex.mu](mailto:malabarfund@apex.mu)

## ANNEXURE – 1

### Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

#### Part-A- Details of the Acquisition

Name of the Target Company (TC)	Neuland Laboratories Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Malabar India Fund Limited		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited & National Stock Exchange of India Limited		
Details of the acquisition as follows	<b>Number</b>	<b>% w.r.t. total share/voting capital wherever applicable (*)</b>	<b>% w.r.t. total diluted share/voting capital of the TC (**)</b>
<b>Before the acquisition under consideration, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	217,911	2.45%	2.45%
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/others)	Nil	N.A	N.A
c) Voting rights (VR) otherwise than by equity shares	Nil	N.A	N.A
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	N.A	N.A
<b>e) Total(a+b+c+d)</b>	<b>217,911</b>	<b>2.45%</b>	<b>2.45%</b>
<b>Details of acquisition</b>			
a) Shares carrying voting rights acquired	699,185	6.27%	6.27%
b) VRs acquired otherwise than by equity shares	Nil	N.A	N.A
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying	Nil	N.A	N.A





## MALABAR INDIA FUND LIMITED

4th Floor, 19, Bank Street, Cybercity, Ebene 72201, Mauritius  
Tel: + (230) 404 8800 Fax: + (230) 404 8899 Email: [malabarfund@apex.mu](mailto:malabarfund@apex.mu)

voting rights in the TC (specify holding in each category) acquired	Nil	N.A	N.A
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	699,185	6.27%	6.27%
<b>e) Total (a+b+c+d)</b>			
<b>After the acquisition, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	917,096	8.22%	8.22%
b) VRs otherwise than by equity shares	Nil	N.A	N.A
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	N.A	N.A
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	N.A	N.A
<b>e) Total (a+b+c+d)</b>	<b>917,096</b>	<b>8.22%</b>	<b>8.22%</b>
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Merger pursuant to scheme of amalgamation between Neuland Health Sciences Private Limited, Neuland Pharma Research Private Limited and Neuland Laboratories Limited		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	NA		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	May 1, 2018		
Equity share capital / total voting capital of the TC before the said acquisition	Rs 8,88,42,540/- consisting of 88,84,254 equity shares of Rs 10/- each.		
Equity share capital/ total voting capital of the TC after the said acquisition	Rs 11,15,48,890/- consisting of 1,11,54,889 equity shares of Rs 10/- each.		
Total diluted share/voting capital of the TC after the said acquisition.	Rs 11,15,48,890/- consisting of 1,11,54,889 equity shares of Rs 10/- each.		

